相关实验视频

Updated: Jul 20, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

临床基因组组图用于预测高级非小细胞肺癌二线免疫治疗的敏感性

Ying Hua^1,2,3, Ai Wang⁴, Chao Xie³

¹Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Translational lung cancer research

|March 21, 2025

概括

预测晚期非小细胞肺癌 (NSCLC) 免疫检查点抑制剂 (ICI) 的反应至关重要. 结合基因突变和PD-L1表达的临床基因组学名图有效预测NSCLC患者的ICI治疗反应.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
免疫治疗是一种免疫疗法.

背景情况:

免疫检查点抑制剂 (ICI) 改善了晚期非小细胞肺癌 (NSCLC) 的治疗结果.
然而,只有少数患者从ICI中受益,因此需要预测性生物标志物.
在NSCLC中预测对二线ICI治疗的反应仍然是一个挑战.

研究的目的:

确定基因组生物标志物,用于预测高级NSCLC中二线ICI治疗的反应.
构建ICI治疗反应的预测模型.
为了评估临床基因组名录在预测ICI反应中的有效性.

主要方法:

对148名接受二线ICI治疗的NSCLC患者的临床数据和遗传检测结果的回顾性分析.
重新分析原始序列数据以定义共同的检测区域.
在固体瘤中使用基于免疫的响应评估标准 (iRECIST) 评估免疫疗法敏感性.

主要成果:

在耐药病例中,EGFR突变更常见 (41.0%对20.6%,P=0.04).
在EP300中的突变与更大的ICI敏感性有关 (39.7%对15.4%,P=0.01).
纳米图集临床变量,基因组数据和PD-L1表达显示高预测准确度 (AUC 0.780在训练中,0.720在测试中) 并与无进展生存相关.

结论:

临床基因组名图有效地预测了高级NSCLC中二线ICI治疗的反应.
命名图利用了经济和容易获得的变量.
该模型有助于在接受ICI治疗的NSCLC患者的现实世界临床决策.

关键词:

免疫检查点抑制剂 (ICI) 免疫检查点抑制剂先进的非小细胞肺癌 (先进的NSCLC)免疫疗法敏感性免疫疗法敏感性这个名字是名ogramogram.身体突变 - 身体突变

更多相关视频

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...